Harpoon Therapeutics has selected CMC Biologics to develop and manufacture three molecules for cancer treatments at the CDMO’s facilities in California and Washington State, US.
CMC Biologics and Trellis Bioscience have entered into a manufacturing agreement for the process development and production of two of Trellis’ monoclonal antibodies (mAbs).
Catalent has partnered with US non-profit PATH for antibody discovery using the CDMO’s GPEx cell line platform, funded by PATH’s Malaria Vaccine Initiative (MVI).
The Bill & Melinda Gates Foundation’s PATH Malaria Vaccine Initiative (MVI) has selected CMC Biologics for process development and manufacture of specific monoclonal antibodies (mAbs) to test for their capacity to protect humans from malaria infection.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at CMC Biologics, PharmaNet and AAIPharma.
